Last updated: September 13, 2026
Tezepelumab-ekko, marketed as Tezspire by AstraZeneca and Amgen, has established a differentiated position in severe asthma as the first approved anti-thymic stromal lymphopoietin, or anti-TSLP, biologic. Its commercial thesis is based on broad patient eligibility, including patients without an elevated eosinophil or allergic phenotype, rather than on a narrow biomarker-defined population. Sales have grown rapidly from a small launch base, but the product faces intense competition from Dupixent, Fasenra, Nucala, Xolair and Cinqair. The principal risks are payer step-editing, biologic switching, high treatment cost, competing label expansions and the eventual loss of exclusivity in the mid-to-late 2030s.
Tezepelumab-Ekko Market Dynamics, Sales Trajectory and Patent Outlook
What is tezepelumab-ekko and how does Tezspire work?
Tezepelumab-ekko is a fully human monoclonal antibody that binds thymic stromal lymphopoietin, or TSLP, an epithelial-cell cytokine that sits near the top of several inflammatory pathways involved in asthma. By blocking TSLP, tezepelumab suppresses downstream signaling associated with eosinophilic, allergic and other inflammatory asthma phenotypes.
The product is marketed as Tezspire. AstraZeneca and Amgen developed the drug under a global collaboration. AstraZeneca has commercial rights in several major markets, while Amgen participates in development and commercialization in the United States and other territories.
The standard approved regimen is 210 mg administered subcutaneously once every four weeks. The U.S. product initially launched as a prefilled syringe, with an autoinjector presentation added later to improve home-administration convenience.
What is the FDA regulatory status of tezepelumab?
The FDA approved Tezspire on Dec. 17, 2021, under Biologics License Application 761183 for the add-on maintenance treatment of severe asthma in patients aged 12 years and older. The U.S. indication does not require an elevated eosinophil count, an allergic phenotype or another biomarker for treatment eligibility (FDA, 2021).
| Regulatory milestone |
Date |
Significance |
| FDA approval |
Dec. 17, 2021 |
First U.S. approval for tezepelumab |
| U.S. indication |
2021 |
Add-on maintenance treatment for severe asthma in patients aged 12 and older |
| EU authorization |
2022 |
Expanded access to European severe-asthma markets |
| Japan approval |
2022 |
Added a major Asian market |
| U.S. self-administration expansion |
2023 |
Supported home use through the prefilled pen presentation |
Tezspire is not approved as a rescue medicine for acute bronchospasm or status asthmaticus. Its commercial use depends on chronic maintenance treatment and continued adherence.
The broad U.S. label is commercially important. Several competing biologics require or strongly rely on evidence of eosinophilic inflammation, allergic sensitization or oral-corticosteroid dependence. Tezepelumab can be considered across a wider severe-asthma population, although payer policies may still impose clinical criteria.
How large is the market for severe-asthma biologics?
The addressable market is the subset of asthma patients with severe disease despite high-dose inhaled corticosteroids and additional controller therapy. Severe asthma represents a minority of total asthma prevalence but accounts for a disproportionate share of asthma-related hospitalizations, emergency care and systemic corticosteroid exposure.
The biologic market includes:
| Product |
Sponsor |
Primary mechanism |
Commercial positioning |
| Tezspire |
AstraZeneca/Amgen |
Anti-TSLP |
Broad severe-asthma eligibility |
| Dupixent |
Sanofi/Regeneron |
IL-4 receptor alpha blockade |
Strong presence in type 2 inflammation and multiple indications |
| Fasenra |
AstraZeneca |
IL-5 receptor alpha depletion |
Eosinophilic asthma; maintenance dosing advantage |
| Nucala |
GSK |
IL-5 blockade |
Eosinophilic asthma and related inflammatory diseases |
| Xolair |
Genentech/Novartis |
Anti-IgE |
Allergic asthma; long-established franchise |
| Cinqair |
Teva |
IL-5 blockade |
Intravenous eosinophilic-asthma treatment |
Dupixent is the most important commercial competitor because its broad respiratory positioning, physician familiarity and large indication base support strong payer and prescriber access. Dupixent is also used in atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and other diseases, giving Sanofi and Regeneron substantial commercial leverage.
Tezspire’s differentiation is strongest in patients who do not fit neatly into the classic eosinophilic or allergic categories. Its clinical value is less distinctive where a patient already has a clear indication for Dupixent, Fasenra or Nucala and has responded well to that therapy.
What is the financial trajectory of Tezspire?
AstraZeneca’s reported Tezspire revenue increased sharply after launch. Public company disclosures indicate the following trajectory for AstraZeneca-recognized revenue:
| Fiscal year |
AstraZeneca-reported Tezspire revenue |
Commercial interpretation |
| 2022 |
Approximately $55 million |
Early launch and market-access buildout |
| 2023 |
Approximately $139 million |
Rapid uptake in the United States and initial international expansion |
| 2024 |
Not included in this analysis |
Requires the applicable full-year company filing |
The 2022-to-2023 increase was approximately 150% based on AstraZeneca’s reported figures. The growth rate reflects a small launch base, not mature-market penetration. AstraZeneca’s disclosures describe increasing demand, broader reimbursement and continued physician adoption as key contributors (AstraZeneca, 2024).
Reported revenue does not equal the product’s full global sales value. The companies share economics under their collaboration agreement, and accounting treatment can differ between product sales, collaboration revenue, royalties and regional commercialization arrangements. Amgen separately reports Tezspire-related economics in its filings, but the two companies’ figures should not be added without reconciling reporting categories.
No standalone Tezspire operating profit is publicly disclosed. Profitability depends on:
- Net price after rebates and discounts.
- AstraZeneca and Amgen’s revenue-sharing structure.
- Launch, medical-affairs and sales-force spending.
- Manufacturing cost for a large-volume monoclonal antibody.
- Development investment in additional respiratory indications.
- Patient-support and specialty-pharmacy costs.
Tezspire has the potential to become a meaningful respiratory franchise, but its revenue base remains materially smaller than Dupixent, Fasenra and Nucala. The product must continue to grow through new starts, switching from other biologics and use in biomarker-low patients.
Which factors are driving Tezspire market growth?
The leading growth drivers are its broad label, physician interest in upstream pathway inhibition and a large pool of severe-asthma patients who remain uncontrolled despite existing therapies.
Broad phenotype coverage
The absence of a mandatory biomarker in the U.S. label expands the theoretical treatment population. This is especially relevant for patients with low or variable eosinophil counts, mixed inflammatory features or inadequate response to existing biologics.
The label does not guarantee unrestricted access. Commercial and government payers can require documentation of severe disease, high-dose inhaled corticosteroid use, exacerbation history and failure or intolerance of other therapies.
Reduction in exacerbation risk
The pivotal NAVIGATOR study demonstrated a reduction in annualized asthma exacerbations compared with placebo in a broad severe-asthma population. The SOURCE study did not meet its primary endpoint for reduction in daily oral-corticosteroid dose in the overall population, which limits the strength of the steroid-sparing claim relative to some competitors (Menzies-Gow et al., 2021; Wechsler et al., 2022).
Home administration
The move toward prefilled pens and self-administration can improve convenience and reduce dependence on infusion centers or office-based injections. Home dosing also aligns with specialty-pharmacy distribution and may support persistence.
Additional respiratory indications
A major commercial opportunity is expansion beyond severe asthma. Tezepelumab has been studied in chronic rhinosinusitis with nasal polyps and other type 2 inflammatory respiratory diseases. Competitive results and regulatory decisions in these indications will determine whether Tezspire becomes a multi-indication biologic or remains concentrated in severe asthma.
What competitive pressures could slow Tezspire sales?
Dupixent’s commercial scale
Dupixent has a larger commercial platform, a broader indication portfolio and extensive physician familiarity. Its established use in asthma and multiple atopic diseases can influence treatment selection and payer contracting.
Anti-IL-5 biologics
Fasenra and Nucala have strong positions in eosinophilic asthma. Fasenra’s eight-week maintenance schedule after the loading period is a meaningful convenience advantage over Tezspire’s four-week schedule.
Treatment sequencing
Payers may require patients to try an older or lower-cost biologic before approving Tezspire. This can position Tezspire as a second-line biologic despite its broad label. Conversely, physicians may use it earlier in patients with mixed or low-biomarker disease.
Net-price pressure
The severe-asthma biologic class has multiple competing products. Rebates, preferred formulary placement and contracting can reduce net price and make market share more dependent on payer agreements than on list price.
Biosimilar and interchangeability risk
Tezepelumab is a biologic, so future competition is expected to come from biosimilars rather than conventional small-molecule generics. No tezepelumab biosimilar had received FDA approval by June 2024. Biosimilar entry is unlikely to be an immediate commercial constraint, but the long-term risk increases as key patents expire and biologic manufacturing expertise expands.
What patents protect tezepelumab and when could exclusivity end?
Tezspire’s protection is expected to rely on a layered biologic patent estate covering the antibody, antigen binding, pharmaceutical compositions, manufacturing and therapeutic use. Exact expiration dates can vary by patent family, terminal disclaimers, patent-term adjustment and any regulatory patent-term extension.
Because Tezspire is a biologic, the relevant FDA reference is the Purple Book rather than the Orange Book. The Orange Book is primarily used for approved small-molecule drugs and does not provide the same patent-certification framework for biologics.
| Exclusivity category |
Tezspire position |
| FDA reference product |
Tezspire |
| Reference BLA |
761183 |
| Biologic exclusivity |
12 years from first licensure under U.S. law, subject to statutory rules |
| Biosimilar pathway |
Available after applicable reference-product exclusivity and patent barriers |
| Orange Book listing |
Not the primary patent database for this biologic |
| Paragraph IV challenge |
Not applicable in the conventional small-molecule sense |
| Patent litigation |
No major public U.S. tezepelumab patent dispute identified through June 2024 |
The 12-year U.S. reference-product exclusivity period would extend into late 2033 based on the 2021 approval date, although the precise date depends on the statutory first-licensure analysis. Patent protection may extend beyond or end before that period. Biosimilar applicants can undertake the statutory patent-information exchange process under the Biologics Price Competition and Innovation Act.
What is the likely generic or biosimilar launch scenario?
A conventional generic launch is not expected because tezepelumab is a monoclonal antibody. The relevant scenario is biosimilar entry after the reference-product exclusivity period and resolution of composition, formulation, manufacturing and method-of-use patents.
The likely sequence is:
- Continued branded growth through severe-asthma penetration and switching.
- Expansion into additional respiratory indications if clinical and regulatory outcomes support it.
- Increasing payer pressure as other biologics gain volume and contracting leverage.
- Biosimilar development during the late 2020s or early 2030s.
- Potential U.S. biosimilar entry in the mid-2030s, subject to patent settlements and regulatory approval.
- Gradual erosion rather than an immediate small-molecule-style collapse, because biologic substitution depends on payer policy, physician adoption and interchangeability status.
Manufacturing complexity provides a practical barrier. A biosimilar sponsor must demonstrate analytical similarity, adequate quality controls and a scalable cell-culture process. These requirements raise development costs and reduce the number of likely entrants compared with conventional generic drugs.
How strong is the Tezspire patent and commercial estate?
Tezspire has a strong commercial position but a developing long-term patent profile. The commercial estate is strongest in four areas:
- Upstream mechanism with broad biologic applicability.
- First-mover status in anti-TSLP treatment.
- Broad U.S. severe-asthma label.
- AstraZeneca and Amgen’s global development and commercialization resources.
The estate is weaker where competitors have entrenched treatment protocols, larger indication portfolios or more convenient dosing schedules. Patent strength alone will not determine lifecycle value. New indications, device patents, dosing claims and manufacturing claims will be important in extending the product’s commercial life.
What is the revenue exposure for AstraZeneca and Amgen?
Tezspire is strategically more important to its sponsors than its current revenue contribution suggests. AstraZeneca has a large respiratory portfolio that includes Fasenra, Symbicort, Breztri and other products. Tezspire can fill a differentiated position in severe asthma, but it also competes with AstraZeneca’s own Fasenra franchise.
For Amgen, Tezspire adds a respiratory biologic to a portfolio historically concentrated in oncology, inflammation, cardiovascular disease, bone health and other specialty markets. The product gives Amgen participation in a growing biologic market without requiring sole responsibility for global commercialization.
The principal financial sensitivities are the pace of U.S. patient starts, international reimbursement, biologic switching, gross-to-net discounts and success in new indications. Tezspire would need sustained annual growth and broader use outside its current core population to become a material group-level revenue driver.
What patent litigation and settlement risks affect Tezspire?
No major public U.S. patent litigation involving tezepelumab had materially altered the commercial outlook through June 2024. No conventional Paragraph IV litigation framework applies because Tezspire is licensed as a biologic rather than an ordinary small-molecule drug.
Future litigation risk is more likely to arise from:
- Biosimilar patent challenges.
- Antibody composition or epitope claims.
- Formulation and device patents.
- Manufacturing-process patents.
- Method-of-use claims in respiratory diseases.
- Patent-listing disputes related to biosimilar disclosure.
Settlement agreements could delay biosimilar entry beyond the first legally available date. The financial impact would depend on the number of biosimilar entrants, the scope of the settlement and whether the agreement preserves branded use in additional indications.
How does Tezspire compare with competing severe-asthma biologics?
| Dimension |
Tezspire |
Dupixent |
Fasenra |
Nucala |
Xolair |
| Target |
TSLP |
IL-4Rα |
IL-5Rα |
IL-5 |
IgE |
| Biomarker requirement in core asthma use |
No mandatory U.S. biomarker |
Type 2-oriented clinical selection |
Eosinophilic asthma |
Eosinophilic asthma |
Allergic asthma |
| Standard dosing interval |
Every four weeks |
Every two or four weeks, depending on indication and regimen |
Every eight weeks after loading |
Every four weeks |
Variable |
| Major advantage |
Broad phenotype coverage |
Scale and broad indication base |
Convenient maintenance schedule |
Established eosinophilic positioning |
Long commercial history |
| Main risk |
Payer sequencing and competition |
High competition and contracting |
Biomarker limitation |
Biomarker limitation |
Narrower phenotype |
Key Takeaways
- Tezepelumab-ekko is the active ingredient in Tezspire, the first approved anti-TSLP biologic for severe asthma.
- FDA approval occurred in December 2021 for patients aged 12 years and older with severe asthma.
- The product’s main differentiation is broad eligibility without a mandatory biomarker requirement in the U.S. label.
- AstraZeneca-reported revenue increased from approximately $55 million in 2022 to approximately $139 million in 2023.
- Dupixent is the largest strategic competitor, while Fasenra and Nucala compete strongly in eosinophilic asthma.
- Tezspire’s commercial expansion depends on payer access, switching from established biologics, self-administration and additional indications.
- As a biologic, Tezspire faces biosimilar rather than conventional generic competition.
- U.S. reference-product exclusivity is expected to extend into late 2033 based on the 2021 first approval, while patent protection may run on a different schedule.
- No major public U.S. tezepelumab patent dispute had materially changed the market outlook through June 2024.
- The product has meaningful growth potential but remains a small contributor to AstraZeneca’s and Amgen’s total revenue relative to their largest franchises.
FAQs about tezepelumab-ekko and Tezspire
Is tezepelumab the same as Tezspire?
Yes. Tezepelumab-ekko is the nonproprietary name, and Tezspire is the marketed brand name.
Is Tezspire an anti-IL-5 drug?
No. Tezspire blocks TSLP. Fasenra and Nucala target the IL-5 pathway.
Does Tezspire require high eosinophils?
The U.S. label does not require a specific eosinophil threshold. Payers may impose separate authorization criteria.
Can Tezspire be replaced by a generic inhaler?
No. Tezspire is a monoclonal antibody administered by injection. Any future competition would generally come from biosimilars, not generic inhalers.
What is the main investment risk for Tezspire?
The main risk is slower-than-expected market share expansion because of Dupixent’s scale, established anti-IL-5 therapies, payer step therapy and the absence of a distinct steroid-sparing advantage across the full treated population.
References
AstraZeneca. (2024). Annual report and Form 20-F 2023. https://www.astrazeneca.com/investor-relations/annual-reports.html
Amgen Inc. (2024). 2023 annual report. https://investors.amgen.com/financial-information/annual-reports-and-proxy-statements
Food and Drug Administration. (2021). FDA approves new treatment for severe asthma. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-severe-asthma
Food and Drug Administration. (2024). Tezspire prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org/
Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., et al. (2021). Tezepelumab in adults and adolescents with severe, uncontrolled asthma. New England Journal of Medicine, 384(19), 1800-1809. https://doi.org/10.1056/NEJMoa2034975
Wechsler, M. E., Menzies-Gow, A., Brightling, C. E., Kuna, P., Korn, S., Welte, T., et al. (2022). Evaluation of the efficacy and safety of tezepelumab in oral corticosteroid-dependent asthma. New England Journal of Medicine, 386(3), 229-238. https://doi.org/10.1056/NEJMoa2107514
